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ABSTRACT
Although rinderpest virus (RPV) has been eradicated in the wild, efforts are still continuing to restrict the extent to which live
virus is distributed in facilities around the world and to prepare for any reappearance of the disease, whether through deliberate
or accidental release. In an effort to find an alternative vaccine which could be used in place of the traditional live attenuated
RPV strains, we have determined whether cattle can be protected from rinderpest by inoculation with vaccine strains of the re-
lated morbillivirus, peste des petits ruminants virus (PPRV). Cattle were vaccinated with wild-type PPRV or either of two estab-
lished PPRV vaccine strains, Nigeria/75/1 or Sungri/96. All animals developed antibody and T cell immune responses to the inoc-
ulated PPRV. However, only the animals given wild-type PPRVwere protected from RPV challenge. Animals given PPRV/
Sungri/96 were only partially protected, and animals given PPRV/Nigeria/75/1 showed no protection against RPV challenge.
While sera from animals vaccinated with the vaccine strain of RPV showed cross-neutralizing ability against PPRV, none of the
sera from animals vaccinated with any strain of PPRV was able to neutralize RPV although sera from animals inoculated with
wild-type PPRVwere able to neutralize RPV-pseudotyped vesicular stomatitis virus.
IMPORTANCE
Rinderpest virus has been eradicated, and it is only the second virus for which this is so. Significant efforts are still required to
ensure preparedness for a possible escape of RPV from a laboratory or its deliberate release. Since RPV vaccine protects sheep
and goats from PPRV, it is important to determine if the reverse is true as this would provide a non-RPV vaccine for dealing with
suspected RPV outbreaks. This is probably the last in vivo study with live RPV that will be approved.
The year 2011 saw the final declaration of the global eradicationof rinderpest, one of the most devastating cattle diseases the
world has known. This was the first livestock disease, and only the
second viral disease, ever eradicated, and the global benefits of
rinderpest eradication are estimated to be in the billions of dollars
(1). That is not to say that rinderpest virus (RPV) itself has disap-
peared from the world. A number of laboratories are known to
have isolates of wild-type RPV for scientific or historic reasons or
due to lapses in freezer stock control. Accidental release of RPV
from such a laboratory is thought to be themost likely pathway by
which the virus might reenter the environment (2, 3) although it
might also be deliberately released as an act of sabotage or bioter-
rorism, whether as a natural isolate or as one made by synthetic
biology based on the RPV genome sequences already in databases.
One of the problemswith these rinderpest vaccines is that there
is no way of telling, serologically, which animals have recovered
from disease and which have been vaccinated; in other words,
there is no accepted vaccine able to distinguish infected from vac-
cinated animals (termed a DIVA vaccine). In an emergency re-
sponse, it may be necessary to kill all vaccinated animals in order
to be sure that all traces of RPV have been eliminated. The impact
of a reemergencewould be lessened if a goodDIVAvaccine existed
which could be deployed. A policy of rapid barrier “vaccination to
live,” which spares protected animals, could then be implemented
as soon as there was a genuine likelihood that RPVhad reemerged.
In the absence of a DIVA vaccine, use of the existing RPV vaccine
is likely to be delayed until there has been reference laboratory
confirmation of RPV, and implementation could be further de-
layed/inhibited if it is known that even vaccinated animals will
later be culled to reinstate the RPV-free status.
RPV is a member of a small group of viruses of the genus
Morbillivirus, which includes measles virus (MV), canine distem-
per virus (CDV), and peste des petits ruminants virus (PPRV).
PPRV causes a severe disease in sheep and goats, and it was found
early on that giving the rinderpest vaccine to sheep and goats
protected them from PPRV (4). Subsequently, attenuated forms
of PPRV were developed to use as vaccines (5, 6), and these are
now used globally to control PPR disease. One such vaccine was
also shown to elicit an immune response in sheep and goats that
would prevent the replication of RPV in those animals (7). What
has not been tested is whether the PPRV vaccine strains could
protect cattle against RPV. If one or more of the PPRV vaccines
protect cattle against rinderpest, they would act as effective DIVA
vaccines. Well-established tests exist that can distinguish between
anti-RPV and anti-PPRV antibodies (8–10). So it would be possi-
ble to distinguish clearly between RPV-infected and PPRV-vacci-
nated animals, and it would still be possible to screen for RPV
infections during and after vaccination. In addition, the natural
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reluctance to deploy rinderpest vaccine, even in the case of a sus-
pected reappearance/release of rinderpest, would not be a prob-
lem if we could deploy one of the widely used PPRV vaccines
instead.
Another advantage of being able to use PPRV vaccines against
RPVwould be that we would no longer have tomaintain stocks of
rinderpest vaccine around the world, and these could be elimi-
nated, reducing costs for at-risk countries as well as eliminating a
potential source of contamination for laboratory samples. Total
removal of RPV from as many facilities as possible is the best
solution to this problem. PPRV vaccines are in production in a
number of countries, and it would be possible to produce and put
into the field large amounts of such vaccine at very short notice in
the case of even a suspected rinderpest reappearance.
Because of these potential benefits, a test of the ability of PPRV
vaccines to protect cattle from rinderpest disease was therefore
approved by theWorld Organisation of Animal Health (OIE) and
the United Nations Food and Agriculture Organization (FAO),
despite the general prohibition on carrying out in vitro or in vivo
work with live RPV.We show here that while wild-type PPRV can
protect cattle from challenge with wild-type RPV, neither of the
two most widely used vaccine strains of PPRV was able to protect
vaccinated cattle, even when used at 20 doses of vaccine per
animal.
MATERIALS AND METHODS
Cells and viruses. Vero-derived cells lines were as previously described
(11). Wild-type PPRV/Ivory Coast/89 (IC89) and PPRV/Nigeria/75/1
(N75) were grown on Vero cells expressing canine SLAM (Vero-dog-
SLAM, or VDS, cells); a cloned RPV vaccine strain (the Plowright vaccine,
also sometimes referred to as RBOK) (RPvacc) (12) was grown on Vero
cells expressing human SLAM (Vero-human-SLAM, or VHS, cells);
PPRV/Sungri/96 (S96) was a gift from MSD Animal Health; RPV chal-
lenge virus (RPV/Saudi/81) (RPwt, wherewt is wild type)was a previously
validated stock of lyophilized spleen from an infected cow. All viruses
were titrated on VDS cells (in general, we observed a 20-fold increase in
titer ofwild-type PPRV/RPV stocks determined onVDS cells compared to
results on unmodified Vero cells).
Animal studies. All animal studies were carried out under licenses
issued by the Home Office of the United Kingdom in accordance with
relevant legislation and after approval by The Pirbright Institute (TPI)
Animal Welfare and Ethical Review Board.
For study 1, two groups of goats (9 to 12 months old), each consisting
of five animals, were inoculated with a standard dose (2 104 50% tissue
culture infectious doses [TCID50] determined in VDS cells [VDS
TCID50], equivalent to 10
3 TCID50 determined in Vero cells) of S96 or
cloned N75, given subcutaneously. Two cohoused animals were left un-
vaccinated to act as controls for the challenge virus. After 4 weeks, the
animals were infected with 2  105 VDS TCID50 of IC89, also given
subcutaneously. Blood samples were collected on various days postvacci-
nation (dpv) and postchallenge infection (dpi) for preparation of serum.
For study 2, 30maleHolstein-Friesian cattle (approximately 4months
old) were used in five groups of 6 animals each. Four groups were vacci-
nated by subcutaneous injection with different viruses: (i) 2  104 VDS
TCID50 of RPvacc, (ii) 4  10
5 VDS TCID50 of IC89, (ii) 4  10
5 VDS
TCID50 of S96, and (iv) 4  10
5 VDS TCID50 of N75. One group of
animals was kept as unvaccinated controls. Blood samples were collected
on various dpv and dpi for serum, for the preparation of peripheral blood
mononuclear cells (PBMCs), and for viral RNA extraction. PBMCs were
prepared by density gradient centrifugation on Ficoll-Paque (GE Health-
care Life Sciences) using standard protocols and frozen in aliquots for
later assay of T cell proliferation.
Clinical scores for both PPR and RP disease were calculated based on
rectal temperatures and other clinical signs. A score of 1 was given for
rectal temperatures 0.5 to 1.9°C above normal for the animal, and a score
of 2was given for temperatures1.9°C above normal. Similarly, a score of
1 was given for ocular or nasal congestion, congestion of the gums, a soft
stool, or apathetic behavior; a score of 2 was given for visible ocular/nasal
discharge, 1 to 2 lesions in the gums, fluid diarrhea, or failure to eat; a
score of 3 was given for profuse ocular/nasal discharge, necrotic oral le-
sions, blood in the diarrhea, or failure to stand. The cumulative score on
each day was recorded as the final clinical score.
Antibody neutralization of RPV and PPRV. All sera were heated at
56°C for 2 h before assay to inactivate any remaining virus in the serum as
well as to inactivate complement. Virus-neutralizing titers of sera from
infected animals were assayed in 96-well plates by standard procedures
(13). The target viruses were N75 for PPRV-neutralizing antibodies and
RPvacc for RPV-neutralizing antibodies, and the cells were VDS cells. The
neutralizing titer was expressed as the reciprocal of the antibody dilution
at which 50% of the wells showed virus growth.
Antibody quantitation by cELISA. A competition enzyme-linked im-
munosorbent assay (cELISA; The Pirbright Institute) for the PPRV hemag-
glutinin protein (PPRV-H) and a PPRV nucleoprotein (PPRV-N) cELISA
(IDVet) were performed according to the manufacturers’ protocols.
VSV pseudotype-based assay for virus neutralizing antibody. Re-
combinant vesicular stomatitis virus (VSV) in which the glycoprotein (G)
gene has been deleted (VSVG) and replaced with firefly luciferase (luc)
has been described previously (14, 15) and was kindly provided by Mi-
chaelWhitt, Memphis, TN. An initial stock of VSVG luc bearing VSV-G
was used to infect 293T cells transfectedwith theVSV-G expression vector
pMDG (16). VSVG luc (VSV-G) pseudotypes were recovered, titrated
on 293T cells, and used to prepare aworking stock of VSVG luc (VSV-G)
pseudotypes. To prepare constructs expressing PPRV-H and the PPRV
fusion protein (PPRV-F), the completeH and F open reading frames were
amplified from the N75-encoding plasmid pCI-PPRV-delL (17) using
the primers PPRV-H-NotWtF (5=-CCGGCGGCCGCACCATGTCCG
CACAAAG-3=) and PPRV-H-BamH1R (5=-GGGGGATCCTCAGACT
GGATTACATGTT-3=) for the H gene and PPRV-F-Wt-NotF (5=-GG
GGCGGCCGCACCATGCATGCGCCGA-3=) and PPRV-F-BamH1-
WtR (5=-GGGGGATCCGCCTACAGTGATCTCACGT-3=) for the F
gene. The rinderpest H cDNA was amplified in two steps from the
Kabete O strain plasmid pT7KOH. First, the primers RPHsalMUTFwd
(5=-GGACGTCGACATGACCATGATTACGCCAAGCTCTAATACGACT
CACTATAGGGAAAGCTTGCATGCCTGCAGA-3=) and RPHsalmutREV
(5=-TAAGCGTCTACCCTGTCTCTTG-3=) were used to amplify a short
product that eliminated an SalI cloning site. The product of this amplifi-
cation was then used in conjunction with the primer RinderpestHnotrev
(5=-GCATGCGGCCGCCTATTTCCCATTGCAAG-3=) to amplify the
full-lengthHcDNA.The rinderpest F cDNAwas amplified frompT7KOF
using the primers RinderpestFsalFwd (5=-GCAAGTCGACATGAAGATC
TTATTTGC-3=) and RinderpestFnotrev (5=-GCATGCGGCCGCCTACA
GTGACCGTACGTA-3=). All amplifications used an Expand High Fidel-
ity PCR system (Roche) and were performed under the following
thermocycling conditions: denaturation at 94°C for 5min, followed by 35
cycles of 94°C for 30 s, annealing at 50°C to 64°C (depending on the
midpoint temperature [Tm] of the primers) for 60 s, and extension at 72°C
for 120 s, with a final extension at 72°C for 10min. Products were digested
with the enzymes BamHI andNotI and cloned into the eukaryotic expres-
sion vector VR1012 (Vical, Inc.). The nucleic acid sequences of all ampli-
fied cDNAs were determined externally by Sanger dideoxy chain termi-
nation sequencing (LIGHTrun Sequencing Service, GATC Biotech AG,
Cologne, Germany). All oligonucleotide primers were obtained from In-
tegrated DNA Technologies, Leuven, Belgium.
To prepare VSVG pseudotypes incorporating a luciferase marker
gene and bearing the envelope glycoproteins of either PPRV or RPV
[VSVG luc (PPRV) or VSVG luc (RPV), respectively], 293T cells were
transfected with either the PPRV-H and -F expression constructs or those
for RPV-H and -F, followed by superinfection with VSVG luc (VSV-G)
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as described previously (14, 15). Supernatants were harvested at 48 h
postinfection, aliquoted, and frozen at80°C. The titer of each viral pseu-
dotype stock was estimated by preparing serial dilutions in triplicate and
plating the stock onto 293dogSLAMcells, followed by incubation for 48 to
72 h at 37°C, at which time luciferase substrate was added (Steadylite Plus;
PerkinElmer), and the signal was analyzed on a Microbeta 1450 Jet lumi-
nometer (PerkinElmer). The TCID50 of the pseudotyped virus was calcu-
lated using the Spearman-Kärber formula (18). Inhibition of luciferase
expression from the VSVG luc pseudotypes by experimental serum was
determined as previously described (19), and the neutralization titer was
defined as the reciprocal of the serumdilution at which the luciferase yield
was reduced by 50%.
T cell proliferation assay. Proliferation of T cells in response to virus
antigen wasmeasured by amodification of themethod of Lund et al. (20).
Virus-specific antigen was prepared from VDS cells infected with N75 or
RPvacc at a multiplicity of infection (MOI) of 0.01 and incubated until
syncytia were well established. The infected cells were scraped into their
medium and centrifuged at 2,500 rpm for 20 min. The pellet was resus-
pended in sterile phosphate-buffered saline (PBS), and virus was inacti-
vated at 56°C for 2 h. Virus antigen was extracted by three rounds of
sonication for 1 min and centrifugation for 20 min at 7,600 rpm in a
microcentrifuge, pooling the supernatants at each extraction. The pooled
supernatant was then spun at 28,000 rpm for 2.5 h in a Beckman 70.1 Ti
rotor, and the final pellet was resuspended in PBS–10% sucrose. Protein
concentration was determined using Bradford reagent (Bio-Rad). Unin-
fected VDS cells were processed in the same way to create the control
antigen.
PBMCs from vaccinated cattle were cultured in RPMI medium con-
taining 10% fetal calf serum (FCS), 1 nonessential amino acids, 1 mM
sodium pyruvate, 50 M 2-mercaptoethanol, and 10 g/ml gentamicin.
Cells were distributed in round-bottomed 96-well plates at 2  105 cells
per well and cultured for 6 days in the presence of 20 g/ml specific or
control antigen. [3H]thymidine (37 kBq) was added to each well 18 h
before the end of the incubation. Cells were harvested onto filters, and the
incorporated 3H was measured by scintillation counting. A stimulation
index was calculated as the ratio of counts incorporated in cells incubated
with specific antigen to counts incorporated in cells incubated with the
control antigen.
RT-qPCR for RPV RNA.Whole blood was taken in EDTA Vacutain-
ers. Total RNA was extracted using an LSI MagVet Universal Isolation kit
(Thermo Fisher) on a MagMax Express-96 processor. RPV RNA was as-
sayed by quantitative reverse transcription-PCR (RT-qPCR) in 5l of the
extracted RNA using AgPath-ID one-step RT-PCR reagents and a modi-
fication of the primer/probe set L10 described by Carrillo and colleagues
(21), inwhich the probe had a 3= quencher/minor groove binder (Thermo
Fisher) in place of the 3= 6-carboxytetramethylrhodamine (TAMRA)
quencher used in the original study, as this was required to allow the probe
to work at 60°C. Results are expressed as the mean 40-CT value, where CT
is the threshold cycle. Each blood sample was extracted twice, and each
extract was assayed by RT-qPCR in duplicate.
Statistical analysis. Statistical analysis of experimental data was car-
ried out using standard functions in R. In most cases, data were fit to a
general linear or polynomial model using the function lme, with individ-
ual animals as random factors, and multiple pairwise comparisons were
carried out using the Tukey analysis option of the glht function. T cell
proliferation data did not fit the normality expectation and so were ana-
lyzed by a Kruskal-Wallis nonparametric test with correction formultiple
comparisons (function kruskalmc).
Rinderpest biocontainment. All studies with live RPV and PPRV
were carried out in the containment facilities of The Pirbright Institute.
The laboratories and animal units operate a biosecurity standard specific
for group 4 (high-impact) livestock pathogens that are not harmful to
humans, as described in the document Animal Pathogens: Guidance on
Controls” issued by the United Kingdom Department for Environment,
Food, and Rural Affairs (22). In addition, the facilities are designed to
meet or exceed the “Minimum Standards for Laboratories working with
FMD in vitro/in vivo,” a standard adopted by the 38th General Session of
the European Commission for the Control of Foot-and-Mouth Disease
on 30 April 2009 (23). The Pirbright Institute is an approved FAO-OIE
rinderpest holding facility, and the study with live rinderpest virus was
approved by the FAO and OIE.
RESULTS
Validation of PPRV vaccine strains. The PPRV vaccine strains
chosen for the study were the original vaccine strain derived from
isolate PPRV/Nigeria/75/1 (N75) (5), used throughout Africa, the
Middle East, and most of Asia, and the most commonly used of
those derived in India, Sungri/96 (S96) (24). In order to be sure
that our vaccine stocks were functional, they were first tested in
goats to show that they were normally immunogenic and gave
protection against wild-type PPRV. Five goats were vaccinated
with each PPRV vaccine strain. Antibody responses to vaccination
were checked by competition ELISA (cELISA) (Fig. 1a and b) and
also by virus neutralization titer (VNT) (Fig. 1c and d). In the
latter case, VNTs were determined separately against both N75
and S96. All vaccinated animals gave strong anti-PPRV antibody
responses. The antibodies raised by the two vaccines neutralized
either virus. Although the sera from animals vaccinated with N75
neutralizedN75more effectively (higher functional titer) than any
other combination (Fig. 1c and d), there was no significant differ-
ence between the results for any other combination of vaccine and
neutralizing target. The antibodies elicited by N75 were better at
displacing monoclonal antibody from ELISA antigen prepared
fromN75 virus (Fig. 1a) or bacterially expressed antigen based on
the N75 sequence (Fig. 1b). However, it was clear that both vac-
cine preparations were immunogenic, and there was strong cross-
reaction between the PPRV vaccines from different lineages.
After 4 weeks, all the goats, plus two unvaccinated control an-
imals, were challenged with IC89, which has previously been
found to be pathogenic in goats in the United Kingdom (25, 26).
Both unvaccinated animals developed full PPR disease, and one
had to be euthanized at 11 days postchallenge (Fig. 2). None of the
vaccinated animals showed any clinical signs (Fig. 2), indicating
that the vaccine stocks were working as expected.
Serum response to PPRV strains in cattle. To assess immune
responses in cattle to PPRV, groups of six Holstein-Friesian cattle
(4 to 5 months old) were vaccinated with (i) the standard Plow-
right RPV vaccine strain (27) (RPvacc), (ii) 20 the normal dose
of N75, (iii) 20 the normal dose of S96, or (iv) the same dose
(4 105 TCID50) of IC89 or were left unvaccinated. The immune
response to the inoculated viruses was observed over 4weeks, after
which the animals were challenged with wild-type RPV (RPwt);
for this we used RPV/Saudi/81, one of the most virulent RPV
isolates ever characterized (28) and the challenge virus used in our
previous studies with RPV (12, 29–31).
Sera taken from experimental animals were tested for their
ability to inhibit cell infection by RPV (RPvacc) and PPRV (N75)
in standard microneutralization assays (Fig. 3). All animals inoc-
ulated with one of the strains of PPRV developed PPRV-neutral-
izing antibodies (Fig. 3a). Interestingly, the antibodies elicited by
the RPV vaccine also neutralized PPRV. The titer of neutralizing
antibody against N75 appeared highest in animals given IC89,
which had statistically significantly higher titers than those seen in
animals given S96 or RPvacc (P  0.001). The titer observed in
animals inoculated with N75 was intermediate, not significantly
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different from those elicited by either S96 or IC89 though signifi-
cantly higher than the titers in animals given RPvacc (P 0.017).
When the sera were tested against RPV, a very different picture
emerged. While the RPV vaccine strain, as expected, elicited a
good titer of RPV-neutralizing antibodies, none of the antibodies
elicited in any of the experimental animals by any of the PPRV
strains had RPV-neutralizing activity (Fig. 3b), with the exception
of sera from 2 of the 6 animals given IC89, which showed very low
RPV-neutralizing titers (10) at 28 dpv. In all other PPRV sera,
RPV-neutralizing titers were below detectable limits.
In case there were neutralizing antibodies which were present
at levels below those detectable by the traditional microneutral-
ization assay, we also assayed neutralizing antibodies using amore
sensitive vesicular stomatitis virus (VSV) pseudotype system (19)
based upon a replication-defective VSV (VSVG) incorporating a
luciferase marker gene and bearing the envelope glycoproteins of
either PPRVorRPV.Using such pseudotyped viruses inwhich the
envelope glycoproteins were those of PPRV (N75 strain) and RPV
(the Kabete O strain fromwhich RPvacc was derived), we found a
similar picture (Fig. 3c and d) as for the classic neutralization assay
but with increased sensitivity at low titers of specific antibodies.
Perhaps because of this higher sensitivity, the assay also saturated
at very high titers (1/32,000). All the vaccinated animals had
anti-PPRV activity by this assay although there was no statistical
difference between the N75, S96, and RPvacc groups. The IC89
group again had higher anti-PPRV activity than any of the others
(P  0.01). The higher sensitivity of this assay at low titers of
specific antibody enabled us to clearly show the presence of RPV-
neutralizing antibodies in the sera of animals vaccinated with
IC89. The levels of anti-RPV antibody were lower in the IC89
group than in the RPV group (P 0.001) but higher than in either
the S96 (P 0.002) orN75 (P 0.001) group. Although therewas
a suggestion in the data that the S96 group also had some RPV-
neutralizing activity (Fig. 3c and d), results for this groupwere not
statistically different from those for the N75 group. None of the
N75-vaccinated animals had significant (titer of 32) anti-RPV
activity.
The antibody responses in the vaccinated animals were also
examined by a different type of serological assay, measuring the
ability of antiserum to compete for specific epitopes on the viral H
proteins in a competition ELISA (cELISA). Sera were tested for
activity in the H protein-specific cELISAs for anti-RPV and anti-
PPRV antibodies (8). The data from these assays correlated well
with the data from the neutralization assays. All animals given
PPRV developed anti-PPRV-H antibodies (Fig. 3e). In addition,
animals immunized with RPvacc developed antibodies which
cross-reacted in the PPRV cELISA, as previously reported (8).
Anti-PPRV-H activity was highest in the animals given IC89 and
was statistically higher than that seen for the group given S96 (P
0.003) or that given RPvacc (P  0.001). The titers in the group
givenN75were again intermediate, being significantly higher than
those of the RPvacc group (P  0.002) but not significantly dif-
ferent from those of either the S96 group or the IC89 group.
It was previously shown that the RPV-H protein cELISA is
entirely specific for RPV-directed antibodies (8), and that was also
observed here, with a strong anti-RPV antibody activity in the sera
from the RPvacc group; no anti-RPV activity was detected in any
of the other groups prior to challenge (Fig. 3f).
Proliferative (T cell) responses to PPRV strains in cattle.The
generation of RPV- or PPRV-specific T cells was studied by look-
FIG 1 Antibody response in goats to PPRV vaccine stocks. Goats were vacci-
nated with either the Sungri/96 or Nigeria/75/1 vaccine strain of PPRV as
described in Materials and Methods. Sera collected at the indicated days post-
vaccination (dpv) or postinfection (dpi) withwild-type PPRVwere assayed for
anti-PPRV antibodies by cELISA using the PPRV-Hprotein-specific ELISA kit
(a), cELISA using the PPRV-N protein cELISA kit (b), neutralization of the
infection of VDS cells by PPRV Nigeria/75/1 (c), and neutralization of the
infection of VDS cells by PPRVSungri/96 (d). Blue bars indicate samples taken
before challenge with wild-type PPRV; pink bars indicate samples taken after
challenge. Error bars show 1 standard error. (Note that due to differences in
the way that the two cELISA kits calculate their results, a positive result in the
PPRV-H cELISA is indicated by an increase in the plotted value [percent in-
hibition], while a positive result in the PPRV-N cELISA is indicated by a de-
crease in the plotted value [percent bound]).
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ing at the stimulation of proliferation of PBMCs incubated with
viral antigen (20). Responses in these outbred animals were, as
expected, variable, and the proliferative responses to the vaccine
viruses were weak; nevertheless, we found that animals vaccinated
with RPvacc generated a clear T cell response to RPV antigen (Fig.
4a). Similarly, animals vaccinated with IC89 or N75 showed a
proliferative response to PPRV antigen (Fig. 4b). The response in
the animals vaccinated with S96 was not statistically significantly
different from that in unvaccinated animals. The proliferative re-
sponse to PPRV antigen appeared slightly stronger in the N75
group, which may reflect the homologous nature of the antigen
used to stimulate proliferation. Aweak RPV-specific response was
seen also in some of the animals vaccinated with different strains
of PPRV (Fig. 4a), but this was statistically significant only for the
IC89 group.
Challenge with wild-type RPV. The vaccinated and unvacci-
nated animals were challenged by inoculation with RPwt. The
unvaccinated controls developed classic rinderpest disease, with
high temperatures, ocular and nasal discharge, and in several cases
gum lesions and diarrhea (Fig. 5). All of these animals were eutha-
nized by 7 dpi. The animals previously given the RPV vaccine
strain were protected from disease, showing no pyrexia and no
significant clinical signs (some animals in all groups developed
slight congestion in the eyes, whichmay have been a result of dust
from hay feed but was not related to any other sign of rinderpest
disease). The group of animals inoculated with IC89 were pro-
tected from rinderpest disease, with no significant difference in
the temperature profiles or mean clinical scores between this
group and the group given the RPV vaccine strain (P 0.001). In
contrast, neither of the PPRV vaccine strains was able to protect
animals from disease. Animals vaccinated with N75 were almost
indistinguishable from the group of unvaccinated animals (Fig.
5), with 5 out of 6 animals having to be euthanized by 7 dpi. The
S96 vaccine gave partial protection such that the animals in this
group displayed amilder set of clinical signs, less extreme pyrexia,
and resolution of the disease by the end of the study. There was no
significant difference in the mean clinical scores for the N75 and
unvaccinated groups, while there were significant differences be-
tween those for the S96 and N75 (P 0.001) groups and between
the S96 and unvaccinated (P  0.001) groups. However, all ani-
mals in the S96 group showed classic rinderpest disease signs and
were clearly significantly sicker (higher mean clinical score) than
animals in the IC89 or RPvacc group ((P 0.001).
Effect of vaccination on viremia in RPV-challenged animals.
The replication of the challenge virus in the experimental animals
was further characterized by measuring rinderpest virus RNA in
blood samples taken at approximately 2-day intervals over the
challenge period. Total RNA was extracted from blood, and the
rinderpest virus RNA was measured by one-step reverse-tran-
scription real-time PCR. The threshold cycle (CT) was taken as a
measure of the relative amount of viral RNA in the blood of each
animal on the respective days (Fig. 6). In the two groups showing
severe disease (unvaccinated and vaccinated with N75), virus
RNA climbed sharply at around 3 dpi, peaking at around 6 dpi.
Interestingly, even though the clinical state of the animals contin-
ued to deteriorate after 6 dpi, the level of virus in the blood did not
increase, and in some animals it declined. This may reflect a con-
tinued loss of white cells in the blood of animals suffering severe
rinderpest disease. The animals that were protected from disease
(vaccinated with RPvacc or IC89) showed no RPV RNA or only
FIG 2 Protection of goats from virulent PPRV challenge by PPRV vaccines. Goats vaccinated with PPRV as described in the legend of Fig. 1 were challenged with
virulent PPRV/Ivory Coast/89 at 28 days after vaccination. (a and b) Rectal temperatures of the two groups of vaccinated animals. (c) Rectal temperatures of the
twounvaccinated control animals. (d)Clinical scores of the twounvaccinated control animals. Animal 12was euthanized at 11 days postchallenge. Clinical scores
of vaccinated animals were zero at all time points.
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very low levels, which disappeared by 9 dpi. As was the case with
the clinical scores, the animals vaccinated with S96 presented an
intermediate picture, with higher and more prolonged viremia in
some animals than seen in any in the RPvacc and IC89 groups but
significantly lower levels than seen in animals in the unprotected
groups. There was no statistical difference between the viremia
levels seen in the RPvacc and IC89 groups, while for each of these
the level was clearly lower than the level seen in the unvaccinated
or N75-vaccinated group (P 0.001 for all). There was a statisti-
cally significant difference between results for the unvaccinated
and those for the N75-vaccinated groups (P 0.0047), reflecting
the fact that one animal in the latter group survived. The viremia
in the S96 group was not statistically different from that in the
RPvacc or IC89 group but was lower than the level seen in either
theN75 group (P 0.024) or the unvaccinated group (P 0.001).
Antibody responses in RPV-challenged animals. After chal-
lenge, anti-RPV antibodies could be detected in the sera of all of
the PPRV-inoculated animals that survived, whether measured as
RPV-neutralizing antibody (Fig. 3b) or as neutralization of the
RPVpseudotypedVSV (Fig. 3d) or in the RPV-H cELISA (Fig. 3f).
FIG 3 Antibody response in cattle to vaccination with PPRV strains or RPV vaccine. Cattle were inoculated with RPV vaccine or different PPRV strains as
described inMaterials andMethods. Sera were collected at the indicated days postvaccination (dpv) or postinfection (dpi) with virulent RPV. Serum antibodies
recognizing RPV or PPRVwere assayed before (blue bars) and after (pink bars) challenge with virulent RPV. Error bars show 1 standard error (no standard error
could be calculated for the N75 group at 14 dpi since only one animal survived to that point). (a) Neutralization of the infection of VDS cells by PPRV
Nigeria/75/1. (b) Neutralization of the infection of VDS cells by RPV vaccine. (c) Neutralization of PPRV-pseudotyped VSV entry into 293-SLAM cells. (d)
Neutralization of RPV-pseudotyped VSV entry into 293-SLAM cells. (e) cELISA using a PPRV-H protein-specific ELISA kit. (f) cELISA using an RPV-H
protein-specific ELISAkit. As negative serumhas a knownnonspecific effect in the cELISAs, we show also the results for the unvaccinated animals for these assays.
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Animals that were fully protected (RPvacc or IC89) showed no, or
only a small, increase over the level seen before challenge, while
the N75- and S96-vaccinated animals showed a stronger boost in
RPV-neutralizing antibodies. The cross-neutralizing ability of an-
ti-RPV antibodies on PPRV, seen previously after vaccination
(Fig. 3a and c), was again observed, with animals originally inoc-
ulatedwith the PPRVvaccine strains showing an increase in PPRV
neutralizing activity (Fig. 3a), as well as slight increases in PPRV
pseudotype neutralization. Just as the antibodies elicited by vacci-
nationwith RPvaccwere positive in the PPRV-H cELISA (Fig. 3e),
so the RPV challenge gave rise to antibodies that increased the
activity in this assay.
DISCUSSION
Cross-reaction, cross-neutralization, and cross-protection be-
tween different morbilliviruses have been studied for many years
and in many different animals, primarily focusing on the well-
established relationships betweenmeasles virus (MV), canine dis-
temper virus (CDV), and RPV (32–37). Much of our knowledge
comes from early studies as the relationships between these vi-
ruses were established by such functional studies and before mo-
lecular techniques became available. It is well established that nat-
urally occurring or specifically induced antiserum against any
morbillivirus cross-reacts with proteins of any other virus in the
same genus (33, 35, 38–42). However, cross-protection induced
by different morbilliviruses is not always a reciprocal relationship
and depends a great deal on the virus strains and animals used, so
that Goret et al. found that wild-type CDV could protect cattle
from RPV while RPV provided only partial protection of ferrets
against CDV (32). On the other hand, DeLay et al. found that RPV
protected dogs fromCDV, but the wild-type CDV did not protect
cattle from RPV (34). While such differences in observed cross-
protectionmay be due to variation in the ability of some strains of
virus to replicate sufficiently in a heterologous host to trigger a
potent immune response, theymay also indicate fundamental dif-
ferences in the breadth of the immune response in specific cases.
Previous studies on RPV and PPRV have shown that inocula-
tion of goats with the N75 PPRV vaccine could elicit antibodies
that neutralized RPV in cell culture, albeit at a lower titer than the
neutralization of PPRV (7). On the other hand, treatment of goats
with the RPV vaccine strain elicited antibodies that neutralized
RPV, as expected, but showed no, or only trace, neutralizing abil-
ity against PPRV (4). Similar to these findings, we found that none
of the PPRV strains used in our study elicited antibodies that
neutralized RPV infection in cell culture. The presence of good
titers of PPRV-neutralizing antibodies, as well as antibodies that
were positive in the PPRV-specific cELISA, indicated that all three
PPRV strains replicated and were immunogenic in the cattle. De-
spite the low levels of anti-RPV antibodies and the absence of
significant amounts of classically RPV-neutralizing antibodies,
animals inoculatedwith IC89 showed essentially complete protec-
tion against RPV challenge. This is a similar picture to the findings
of Taylor with RPV in goats or to the findings of several authors
that a single inoculation of MV in dogs elicited MV-neutralizing
but not CDV-neutralizing antibodies (37, 43), while protecting
the dogs against CDV (34, 36), or the recent finding that inoculat-
ing macaques with CDV or MV elicited antibodies that were not
cross-neutralizing (44). In the studies reported here, we have used
a more sensitive test for neutralizing antibodies, based on VSV
pseudotypes; this assay revealed the presence of significant anti-
RPV activity in the IC89-vaccinated animals prior to challenge.
Cross-protection may therefore have been mediated by a weak
humoral response (not detected by traditional neutralizing assay
techniques), coupled with an associated cell-mediated response.
The main aim of the study was to see if either of the PPRV
vaccine strains could protect against RPV infection in cattle. Our
data show clearly that they did not. Although both vaccine strains
replicated in the cattle and elicited PPRV-neutralizing antibodies
and PPRV-specific T cells, the best that was achieved was a partial
suppression of RPV replication and consequent clinical signs in
the group of animals inoculated with S96. Animals inoculated
with N75 were essentially indistinguishable, in their levels of clin-
ical rinderpest disease and viremia, from those which were unvac-
cinated. It will therefore not be possible to replace stocks of
RPvacc being held for emergency use with stocks of PPRV vaccine.
An important question is why RPvacc protects goats against
PPRV while the reciprocal protection is not observed for the
PPRV vaccine strains. The most likely reason is the essentially
random nature of the attenuating mutations that arise in these
vaccine strains during serial passage in cell culture. Both the S96
and N75 vaccines have been safe and effective in sheep and goats
over a number of years of use, suggesting that both have acquired
a number of separate attenuatingmutations. The presence ofmul-
tiple attenuating mutations prevents the reversion to virulence of
the strains through any single random base change. Since the na-
ture of these attenuating mutations is uncharacterized, there was
FIG 4 Assay of T cell proliferation in PBMCs from vaccinated animals.
PBMCswere isolated from cattle vaccinated as described in the legend of Fig. 3.
Proliferation in response to stimulation with RPV or PPRV proteins was mea-
sured as described in Materials and Methods and plotted as the cumulative
stimulation index (ratio of thymidine incorporation in response to specific
antigen to incorporation in response to control antigen) for each group of
animals at the indicated day postvaccination. The response in individual ani-
mals is shown by different shades of gray, which make up the cumulative
response.
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FIG 5 Effect of challenge with virulent RPV on vaccinated animals. Cattle were left unvaccinated (a and f) or were vaccinated with the indicated vaccine and
wild-type (wt) viruses (b to e and g to j). All the cattle were infected with virulent RPV at 3 weeks postvaccination. (a to e) The rectal temperatures for individual
animals in each group are shown. (f to j) The clinical score on each daywas calculated as described inMaterials andMethods, and the scores for individual animals
in each group are shown.
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always the possibility that one or more of them would have a
particularly strong effect on the replication or immunogenicity of
the virus in cattle. This was the reason that we tested two indepen-
dently developed PPRV vaccine strains and also included a wild-
type, unattenuated strain of PPRV. Our data show that there is
sufficient immunological similarity between RPV and PPRV for
cross-protection since IC89 protected the cattle from RPV. This
finding is in accord with very early studies, from before the virus
that causes PPR was isolated and characterized, where crude ma-
terial fromanimals suffering fromPPRwas shown to protect cattle
from rinderpest disease (45). However, we found that the vaccine
strains of PPRV are partially (S96) or completely (N75) unable to
induce this immune protection in cattle. There is precedent for
such an effect of attenuation in vaccine strains in that wild-type
CDV protected cattle against RPV, but an attenuated vaccine
strain of CDV did not offer such protection (32). It remains the-
oretically possible, therefore, that targeted attenuation of a wild-
type PPRV isolate to create a new vaccine strain could create one
that cross-protected against RPV in cattle, but such development
work would not be justified, given the relatively low risk of RPV
outbreaks occurring.
The cross-protection observed between morbilliviruses has
been ascribed to cell-mediated immunity rather than to cross-
reacting antibody (36, 37). In our studies we were indeed able to
demonstrate statistically significant RPV-specific T cell-mediated
responses in IC89-inoculated cattle, which was the group that
showed protection against RPV challenge. However, the re-
sponses were weak, and no statistically significant difference could
be shown between results for the different groups of PPRV-inoc-
ulated animals. There may have been additional RPV-specific T
cells in the lymph nodes but in insufficient numbers in the circu-
lating cell population to give a definite response in our assay. Our
use of young animals may have mitigated against detecting the
cell-mediated response since similar studies showed no detectable
cell-mediated immune response toCDV in young pups givenMV,
while it was easily detected when older animals were used (37).
The data shown in Fig. 4 do suggest a slight RPV-specific response
in the PBMCs fromPPRV-inoculated animals, andmore sensitive
tests, such those measuring the proliferation of purified CD4	 or
CD8	 cells extracted from the PBMCs, may reveal a better cell-
mediated immune response to PPRV infection in cattle that reacts
to RPV antigen andmay discriminate better between the different
groups.
Similar to other studies on morbillivirus cross-protection, our
study did not show a correlation between classically assayed RPV-
neutralizing antibody and protection against RPV. None of the
PPRV-vaccinated animals had detectable RPV-neutralizing anti-
bodies but showed complete, partial, or no protection against
RPV, depending on the PPRV strain used. The protection against
RPV that was observed appeared to correlate with the anti-RPV
antibody activity detected by the very sensitive VSV pseudotype
inhibition assay. It may be that very low levels of cross-reactive B
cell selection/activation are all that is required to provide protec-
tion against disease and that the anti-RPV activity we have ob-
served explains the protection against disease provided by IC89
and the limited protection provided by S96. Another possibility is
that cross-protection is indeed mediated by antibody, but not an-
tibody that neutralizes virus directly. Theremay be epitopes on the
surface of morbilliviruses, particularly on the highly conserved
fusion glycoprotein (42, 46), that elicit cross-reactive antibodies
FIG 6 Replication of wild-type RPV in vaccinated cattle. Cattle were left un-
vaccinated (a) or were vaccinated with the indicated vaccine or wild-type (wt)
virus (b to e). All the cattle were infected with virulent RPV at 3 weeks post-
vaccination. RNA was extracted from whole blood taken from experimental
animals at different times after challengewith virulent RPV.RPV-specificRNA
was assayed by reverse-transcription/real-time PCR (RT-qPCR), and the
amount of viral RNA is expressed as the mean 40-CT value, a value which
increases as the amount of viral RNA increases. Values for individual animals
in each group are shown.
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that fix complement, lead to killing of infected cells, or otherwise
inhibit virus growth while not preventing virus infection in cell
culture. It is known that antibodies to the RPV-F protein do not
neutralize virus directly but only in the presence of complement
(47), while similar anti-RPV-H antibodies are directly neutraliz-
ing. Immunofluorescence studies have previously shown the pres-
ence of antibodies in measles serum that recognize the surface
glycoproteins of CDV in the absence of CDV-neutralizing activity
(40).
We have shown that wild-type PPRV protects cattle against
RPV challenge and that this group had significant anti-RPV anti-
bodies and RPV-specific T cell responses not detected in the
groups given either of two PPRV vaccines. It is known frommany
recent serum surveys (48–52) that PPRV circulating in the small
ruminant population can subclinically infect cattle, giving rise to
PPRV-specific antibodies in the sera. It is interesting to speculate
whether such subclinical infections occurred in the past, affecting
the spread of RPV, and similarly whether any of the extensive
spread of PPRV in the last 15 years has been due to the eradication
of RPV. The more-or-less constant presence of measles virus (ei-
ther wild type or vaccine) in human populations for the last 2,000
years may have protected us from disease caused by CDV, which
has now shown itself able to cause disease outbreaks in primates
(53, 54). Determining the exact mechanism of cross-protection
between morbilliviruses will require more extensive characteriza-
tion of the range of antibodies elicited in infection as well as more
detailed dissection of the cell-mediated immune response.
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